SLC5A2 and type 2 diabetes mellitus: More recently, with the increasing use of sodium glucose cotransporter 2 (SGLT2) inhibitors to treat diabetes type 2, the phenomenon of euglycemic diabetic ketoacidosis was recognized as a potential diagnostic blind spot and patient safety concern (7–9).